Ben Gibson spent 13 years banking technology deals at Canaccord Genuity before co-founding Pano Therapeutics, a biotech turning UCSF mitochondrial research into small molecule drugs.
Worth knowing
Ben knows both sides of a hard conversation: how technology companies get valued, sold and financed, and what it takes to move university science toward the clinic, including buying another company to get the research team he wanted. Founders weighing a bank versus a strategic path, and scientists trying to build a company around a target, will get a straight answer.
Story
Ben joined Canaccord Genuity's Montreal office in 2000 and rose to Co-Head of Canadian Technology Investment Banking, then moved to the firm's San Francisco office in 2013 to run technology deals from the Bay Area. In 2017 he left banking to co-found Pano Therapeutics with Francesca Fieni, built on UCSF work identifying a mitochondrial ion channel target tied to Metformin's effects. Pano develops small molecule drugs for diseases of aging, and Ben leads it as CEO from Haleiwa, Hawaii.
Highlights
- Co-founder and CEO, Pano Therapeutics (founded 2017, San Francisco)
- Acquired NovaTarg Therapeutics; appointed Ken Batchelor, PhD, Head of R&D
- Managing Director, Investment Banking, Canaccord Genuity San Francisco (2013)
- Board Member, Pano Therapeutics
More people in United States
See everyone
Jonathan Abrams
Co-founder and General Partner, 8-Bit Capital
Trevor Adey
Co-Founder & General Partner, McVestCo (also associated with Trimac Transportation and 80VC)
Raj Aggarwal
Founder (stealth startup), Stealth startup (previously AWS)
Barb Bidan
Interim Chief People Officer, Ryan (Ryan LLC)
Know someone who belongs here?
Constellation is the directory of Canadians and friends of Canada around the world, written by the people in it. Send them this page, or add your own.
Add Yourself